Recently collected data indicate that naltrindole (NTI), a specific delta opioid receptor antagonist, has features of a useful medicine for treating people abusing cocaine. Although the results from preliminary research are very encouraging, those results are limited by the small numbers of subjects used, and the fact that only a limited range of acute doses of NTI were used. Given both the promise of the initial results and their limitations, the aims are straightforward.
The aim i s to assess the effects of NTI, thereby, laying a basis for the further development of pharmacological agents that safely modify cocaine's positive affective, positively reinforcing potential. More specifically, research is planned, with respect to cocaine's effects, to (a) observe the effects of a range of doses of NTI, (b) determine if NTI is orally effective, and (c) see if NTI's effects change with repeated daily dosing. Additionally, other experiments are planned, for example, to assess NTI's ability to modify responses conditioned to cocaine's effects. Also, NTI's effects will be assessed by testing it with respect to amphetamine's reinforcement. Because NTI may have limiting side-effects, other specific delta opioid receptor antagonists' ability to modify cocaine's effects will be examined.

National Institute of Health (NIH)
National Institute on Drug Abuse (NIDA)
Research Project (R01)
Project #
Application #
Study Section
Special Emphasis Panel (SRCD)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Rensselaer Polytechnic Institute
Schools of Arts and Sciences
United States
Zip Code
Gardell, L R; Reid, M L; Cavallero, C A et al. (1999) Amlodipine, a calcium channel inhibitor, and cocaine and ethanol's reinforcing effects. Pharmacol Biochem Behav 64:567-72
Cramer, C M; Hubbell, C L; Reid, L D (1998) A combination of isradipine and naltrexone blocks cocaine's enhancement of a cocaine place preference. Pharmacol Biochem Behav 60:847-53
Bilsky, E J; Montegut, M J; Nichols, M L et al. (1998) CGS 10746B, a novel dopamine release inhibitor, blocks the establishment of cocaine and MDMA conditioned place preferences. Pharmacol Biochem Behav 59:215-20
Cramer, C M; Gardell, L R; Boedeker, K L et al. (1998) Isradipine combined with naltrexone persistently reduces the reward-relevant effects of cocaine and alcohol. Pharmacol Biochem Behav 60:345-56
Gardell, L R; Whalen, C A; Chambers, M D et al. (1998) Valproate reduces intake of alcoholic beverage among rats. Behav Pharmacol 9:683-9
Pabello, N G; Hubbell, C L; Cavallaro, C A et al. (1998) Responding for rewarding brain stimulation: cocaine and isradipine plus naltrexone. Pharmacol Biochem Behav 61:181-92
Gonzales, P M; Boswell, K J; Hubbell, C L et al. (1997) Isradipine blocks cocaine's ability to facilitate pressing for intracranial stimulation. Pharmacol Biochem Behav 58:1117-22
Gardell, L R; Whalen, C A; Chattophadyay, S et al. (1997) Combination of naltrexone and fluoxetine on rats' propensity to take alcoholic beverage. Alcohol Clin Exp Res 21:1435-9
Reid, L D; Pabello, N G; Cramer, C M et al. (1997) Isradipine in combination with naltrexone as a medicine for treating cocaine abuse. Life Sci 60:PL119-26
Gardell, L R; Reid, L D; Boedeker, K L et al. (1997) Isradipine and naltrexone in combination with isradipine interact with a period of abstinence to reduce rats' intakes of an alcoholic beverage. Alcohol Clin Exp Res 21:1592-8

Showing the most recent 10 out of 14 publications